...
首页> 外文期刊>Critical Reviews in Eukaryotic Gene Expression >Diagnostic, Prognostic, and Therapeutic Potencies of Circulating miRNAs in Acute Myocardial Infarction
【24h】

Diagnostic, Prognostic, and Therapeutic Potencies of Circulating miRNAs in Acute Myocardial Infarction

机译:急性心肌梗死中循环miRNA的诊断,预后和治疗效率

获取原文
获取原文并翻译 | 示例
           

摘要

Acute myocardial infarction (AMI), or heart attack, is a major public health problem, responsible for 3 to 4 million deaths each year. Despite great improvements in diagnostic and therapeutic strategies, it remains one of the most lethal types of heart disease. Therefore, the identification of molecular mechanisms involved in AMI pathogenesis might help us to develop new therapeutic and diagnostic approaches. MicroRNAs (21- to 24-nucleotide noncoding RNAs) have been shown to play important roles in AMI pathogenesis by affecting multiple cellular processes, including cardiac cell proliferation, apoptosis, survival, regeneration, and autophagy. Thus, targeting microRNAs might have great clinical significance for the treatment of AMI patients. Moreover, aberrant miRNA expression patterns can serve as an ideal diagnostic and prognostic biomarker for AMI patients. This review aims to give an overview of recent studies that have addressed the therapeutic potency of microRNAs in AMI. We also summarize the potential use of microRNAs as diagnostic and prognostic biomarkers for AMT.
机译:急性心肌梗死(AMI)或心脏病发作是一个主要的公共卫生问题,每年负责3至400万人死亡。尽管诊断和治疗策略有很大改善,但它仍然是最致命的心脏病类型之一。因此,鉴定AMI发病机制的分子机制可能有助于我们开发新的治疗和诊断方法。通过影响多种细胞过程,包括心细胞增殖,凋亡,存活,再生和自噬,已经证明了MicroRNAs(21至24-核苷酸非编码RNA)在AMI发病机制中起重要作用。因此,靶向MicroRNA可能对AMI患者的治疗具有很大的临床意义。此外,异常miRNA表达模式可以作为AMI患者的理想诊断和预后生物标志物。该审查旨在概述最近的研究,这些研究已经解决了在AMI中的MicroRNA的治疗效力。我们还总结了MicroRNA作为AMT的诊断和预后生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号